Clarithromycin

Generic Name
Clarithromycin
Brand Names
Biaxin, Biaxin Bid, Omeclamox, Prevpac, Voquezna 14 Day Triplepak 20;500;500
Drug Type
Small Molecule
Chemical Formula
C38H69NO13
CAS Number
81103-11-9
Unique Ingredient Identifier
H1250JIK0A
Background

Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.

Indication

An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).

Clarithromycin is indicated in combination with vonoprazan and amoxicillin as co-packaged triple therapy to treat Helicobacter pylori (H. pylori) infection in adults.

Associated Conditions
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Helicobacter Pylori Infection, Infective Endocarditis (IE), Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections
Associated Therapies
-

A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC

First Posted Date
2016-08-02
Last Posted Date
2018-01-18
Lead Sponsor
University Hospital Regensburg
Target Recruit Count
86
Registration Number
NCT02852083
Locations
🇩🇪

MVZ am Klinikum GmbH, Passau, Bavaria, Germany

🇩🇪

Klinik für Innere Medizin, Homburg/Saar, Saarland, Germany

🇩🇪

St. Antonius-Hospital, Eschweiler, Nordrhein-Westfalen, Germany

and more 6 locations

Clarithromycin as Adjuvant to Periodontal Debridement

First Posted Date
2016-07-12
Last Posted Date
2017-11-21
Lead Sponsor
Universidade Estadual Paulista Júlio de Mesquita Filho
Target Recruit Count
40
Registration Number
NCT02829983

To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

First Posted Date
2016-06-21
Last Posted Date
2020-01-29
Lead Sponsor
CTI BioPharma
Target Recruit Count
20
Registration Number
NCT02807051
Locations
🇺🇸

Covance Clinical Research Unit, Daytona Beach, Florida, United States

TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-05-17
Last Posted Date
2016-05-17
Lead Sponsor
Takeda
Target Recruit Count
16
Registration Number
NCT02774902

Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment

First Posted Date
2016-04-08
Last Posted Date
2018-06-26
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
66
Registration Number
NCT02732249
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori

First Posted Date
2016-02-26
Last Posted Date
2017-03-21
Lead Sponsor
Damascus Hospital
Target Recruit Count
74
Registration Number
NCT02693574
Locations
🇸🇾

Damascus Hospital, Damascus, Syrian Arab Republic

The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients

First Posted Date
2016-01-07
Last Posted Date
2018-08-09
Lead Sponsor
Kyungpook National University Hospital
Target Recruit Count
50
Registration Number
NCT02648659

Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy

First Posted Date
2015-12-17
Last Posted Date
2017-01-18
Lead Sponsor
Xijing Hospital of Digestive Diseases
Target Recruit Count
566
Registration Number
NCT02633930
Locations
🇨🇳

Xijing Hospital of Digestive Diseases, Xi'an, Shanxi, China

🇨🇳

Xijing Hospital of Digestive Disease, Xi'an, Shanxi, China

Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma

First Posted Date
2015-12-08
Last Posted Date
2015-12-08
Lead Sponsor
Henrik Gregersen
Target Recruit Count
300
Registration Number
NCT02624440
Locations
🇩🇰

Department of Hematology, Aalborg University Hospital, Aalborg, Denmark

🇩🇰

Department of Hematology, Rigshospitalet, Copenhagen, Denmark

🇩🇰

Department of Hematology, Esbjerg Sygehus, Esbjerg, Denmark

and more 5 locations

GEM-CLARIDEX: Ld vs BiRd

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2015-10-14
Last Posted Date
2022-02-01
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
286
Registration Number
NCT02575144
Locations
🇪🇸

H. del SAS de Jerez, Jerez De La Frontera, Spain

🇪🇸

Hospital Costa del Sol, Marbella, Spain

🇪🇸

Hospital General Universitario Morales Meseguer, Murcia, Spain

and more 23 locations
© Copyright 2024. All Rights Reserved by MedPath